Clinical and Prognostic Significance of Positive Hepatojugular Reflux on Discharge in Acute Heart Failure: Insights from the ESCAPE Trial

Table 3

Short-term and intermediate-term outcomes of patients with or without a positive hepatojugular reflux on discharge enrolled in the ESCAPE trial.

	+ve HJR on discharge; ()	−ve HJR on discharge; ()	value
Mortality % ()	27% (31/115)	14.4% (40/277)	0.004
Composite endpoint of death, rehospitalization, and cardiac transplant % ()	71.3% (82/115)	60.3% (167/277)	0.04
Death due to witnessed cardiac arrest % ()	58.3% (7/12)	13.3% (2/15)	0.021
Number of days of initial hospitalization (days, m ± SD)	8.8 ± 7.4	7.8 ± 5.6	0.228
Total days in hospital in first 180 days	17.6 ± 17.9	16.1 ± 18.7	0.208
Patient received LVAD or cardiac transplant % ()	5.2% (6/115)	8.7% (24/277)	0.247

HJR: hepatojugular reflux; LVAD: left ventricular assist device.